Memorial Sloan Kettering Cancer Center: Hematologic Neoplasms trials

The registry lists 18 Hematologic Neoplasms studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 4 are open to participants now and 9 have results posted.

Phase 1 2Phase 2 11Phase 3 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell TransplantRecruitingNCT07359859Phase 2
• A Music Therapy Study for Blood Cancer Survivors With Cognitive DifficultiesRecruitingNCT07052916Not applicable
• A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell TransplantRecruitingNCT07006506Phase 2
• Genomic Profiling in Cancer PatientsRecruitingNCT01775072
• Study of Benralizumab in People With Skin Side Effects Caused by Cancer TherapiesCompletedNCT04552288Phase 2Results posted
• Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)CompletedNCT03149055Phase 2Results posted
• Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic MalignanciesCompletedNCT03082677Phase 2Results posted
• Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best DonorCompletedNCT02880293Not applicableResults posted
• Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological MalignanciesCompletedNCT01682226Phase 2Results posted
• Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell TransplantationCompletedNCT01596257Phase 2Results posted
• HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic MalignanciesCompletedNCT01119066Phase 2Results posted
• Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.CompletedNCT00739141Phase 2Results posted
• A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological MalignancyCompletedNCT00597519Phase 2Results posted
• Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell TransplantationActive, not recruitingNCT05873205Phase 2
• Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell TransplantationActive, not recruitingNCT04098393Phase 1
• Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell TransplantationCompletedNCT02598752
• Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell TransplantationCompletedNCT00138112Phase 3
• Arsenic Trioxide in Treating Patients With Advanced Hematologic CancerCompletedNCT00003395Phase 1